Literature DB >> 11750297

What are the contributing factors for insomnia in the general population?

M M Ohayon1, T Roth.   

Abstract

Lack of a systematic assessment of insomnia has led to large variations in its reported prevalence in the general population. This study aims to provide new guidelines to assess insomnia prevalence. A cross-sectional telephone survey using the Sleep-EVAL system was done with 24,600 general population-based subjects 15 years and older representative of general populations (France, the UK, Germany, Italy, Portugal, and Spain) consisting of 251,405,391 inhabitants. The overall participation rate was 81.0%. Within the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) symptomatology for insomnia, 27.2% (95% confidence interval: 26.6-27.8%) of the sample reported difficulty initiating sleep (DIS) (10.1%) or maintaining sleep (DMS) (disrupted sleep (DS): 18.0%; early morning awakening (EMA): 10.9%) or nonrestorative sleep (NRS) (8.9%) at least three times per week; 48.5% of them were concomitantly suffering of a DSM-IV sleep/mental disorder. A factor analysis identified several variables strongly related to each of the major factors of insomnia allowing: (1) The narrowing of the definition of insomnia: the prevalence of insomnia decreased to 16.8% with 64.5% of insomnia subjects having a DSM-IV sleep/mental disorder; (2) The identification of a sleep-deprived (voluntary or not) group without insomnia symptoms, representing 2.1% (1.9-2.3%) of the sample. Interestingly, the latter group closely matched the definition of insufficient sleep syndrome as described by the International Classification of Sleep Disorders (ICSD). Using more delineated criteria to assess insomnia increases the recognition of subjects complaining about sleep. Classifications should be amended to improve the correct identification of insomnia. Sleep-deprived subjects should also not be neglected.

Entities:  

Mesh:

Year:  2001        PMID: 11750297     DOI: 10.1016/s0022-3999(01)00285-9

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  54 in total

1.  Development and validation of the Nonrestorative Sleep Scale (NRSS).

Authors:  Kate Wilkinson; Colin Shapiro
Journal:  J Clin Sleep Med       Date:  2013-09-15       Impact factor: 4.062

2.  Perceived racial discrimination and risk of insomnia among middle-aged and elderly Black women.

Authors:  Traci N Bethea; Eric S Zhou; Eva S Schernhammer; Nelsy Castro-Webb; Yvette C Cozier; Lynn Rosenberg
Journal:  Sleep       Date:  2020-01-13       Impact factor: 5.849

3.  Insomnia and the performance of US workers: results from the America insomnia survey.

Authors:  Ronald C Kessler; Patricia A Berglund; Catherine Coulouvrat; Goeran Hajak; Thomas Roth; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; James K Walsh
Journal:  Sleep       Date:  2011-09-01       Impact factor: 5.849

Review 4.  Residual effects of hypnotics: epidemiology and clinical implications.

Authors:  Annemiek Vermeeren
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Effects of stressor controllability on diurnal physiological rhythms.

Authors:  Robert S Thompson; John P Christianson; Thomas M Maslanik; Steve F Maier; Benjamin N Greenwood; Monika Fleshner
Journal:  Physiol Behav       Date:  2013-02-27

6.  Sleep quality and body mass index in college students: the role of sleep disturbances.

Authors:  Perla A Vargas; Melissa Flores; Elias Robles
Journal:  J Am Coll Health       Date:  2014

7.  Sociodemographic profile of insomniac patients across national surveys.

Authors:  François-André Allaert; Renaud Urbinelli
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Sleep disorders and quality of life in renal transplant recipients.

Authors:  Miklos Zsolt Molnar; Marta Novak; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

9.  Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program.

Authors:  Oxana G Palesh; Joseph A Roscoe; Karen M Mustian; Thomas Roth; Josée Savard; Sonia Ancoli-Israel; Charles Heckler; Jason Q Purnell; Michelle C Janelsins; Gary R Morrow
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

10.  Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.

Authors:  Thomas Roth; Steven G Hull; D Alan Lankford; Russell Rosenberg; Martin B Scharf
Journal:  Sleep       Date:  2008-09       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.